The biotechnology company specializes in developing innovative therapies using regulatory T-lymphocytes (TREGS) and combination therapies. Main research areas include treatment of type 1 diabetes in children and multiple sclerosis. The company owns a modern pharmaceutical manufacturing facility with 4,000 sq m of space, including 2,100 sq m of laboratory area, featuring 15 autonomous production lines. The facility has obtained authorization from the Main Pharmaceutical Inspectorate for medicinal product manufacturing. The company conducts clinical trials, including the PreTREG study in pre-symptomatic diabetes and studies in multiple sclerosis. Therapies using next-generation TREGS, including CAR-TREGS, are also being developed.